Vernakalant

Vernakalant (RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic. IC50 value: Target:

Product Specifications

CAS Number

[794466-70-9]

Product Name Alternative

RSD1235

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/vernakalant.html

Solubility

10 mM in DMSO

Smiles

COC1=C(C=C(C=C1)CCO[C@H]2[C@@H](CCCC2)N3CC[C@H](C3)O)OC

Molecular Formula

C20H31NO4

Molecular Weight

349.46

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Dorian, Paul MD et al. The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. Journal of Cardiovascular Pharmacology:July 2007 - Volume 50  -Issue 1 - pp 35-40.|[2]Jodene Eldstrom et al. The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels. Molecular Pharmacology December 2007 vol. 72 no. 6 1522-1534|[3]Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21 (127) :119-22.|[4]Blomstr?m-Lundqvist C, Blomstr?m P.Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.Expert Opin Drug Saf. 2012 Jul;11 (4) :671-9. Epub 2012 May 26.|[5]Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M.Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.Cardiovasc Drugs Ther. 2012 Apr;26 (2) :167-79.